Trials / Completed
CompletedNCT03688204
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer: Impact on Risk Estimates, Management Recommendations, Clinical Outcomes, and Patient Perception
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 118 (actual)
- Sponsor
- Ambry Genetics · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.
Conditions
Timeline
- Start date
- 2018-09-21
- Primary completion
- 2020-11-11
- Completion
- 2020-11-11
- First posted
- 2018-09-28
- Last updated
- 2022-03-07
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03688204. Inclusion in this directory is not an endorsement.